Cargando…

Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system

BACKGROUND: Angiotensin converting enzyme inhibitors (ACE inhibitors) reduce peripheral vascular resistance via blockage of angiotensin converting enzyme (ACE). ACE inhibitors are commonly used to treat congestive heart failure and high blood pressure, but other effects have been reported. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos-Nino, Maria E, MacLean, Charles D, Littenberg, Benjamin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632632/ https://www.ncbi.nlm.nih.gov/pubmed/19061507 http://dx.doi.org/10.1186/1472-6823-8-17

Ejemplares similares

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System
por: Ramos-Nino, Maria E, et al.
Publicado: (2007)

Association between prevalence of obstructive lung disease and obesity: results from The Vermont Diabetes Information System
por: Ramos-Nino, Maria E., et al.
Publicado: (2021)

Limitations of diabetes pharmacotherapy: results from the Vermont Diabetes Information System study
por: MacLean, Charles D, et al.
Publicado: (2006)

Intra-cluster correlation coefficients in adults with diabetes in primary care practices: the Vermont Diabetes Information System field survey
por: Littenberg, Benjamin, et al.
Publicado: (2006)

An association between anti-platelet drug use and reduced cancer prevalence in diabetic patients: results from the Vermont Diabetes Information System Study
por: Holmes, Chris E, et al.
Publicado: (2010)

Potential enhanced association between obstructive lung disease and history of depression in patients with diabetes
por: Ramos-Nino, Maria E, et al.
Publicado: (2021)

Association between the prevalence of obstructive lung disease and the use of aspirin in a diabetic population
por: Ramos-Nino, Maria E, et al.
Publicado: (2022)

Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont
por: Wershoven, Nicole, et al.
Publicado: (2020)

Prevalence of antiplatelet therapy in patients with diabetes
por: Miller, Shaun R, et al.
Publicado: (2005)

The use of adherence aids by adults with diabetes: A cross-sectional survey
por: Littenberg, Benjamin, et al.
Publicado: (2006)

Literacy and health outcomes: a cross-sectional study in 1002 adults with diabetes
por: Morris, Nancy S, et al.
Publicado: (2006)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
por: Aggarwal, Neerja, et al.
Publicado: (2017)

A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
por: Pathak, Jahnavi V., et al.
Publicado: (2015)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

The use of insulin declines as patients live farther from their source of care: results of a survey of adults with type 2 diabetes
por: Littenberg, Benjamin, et al.
Publicado: (2006)

The Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors in Severe Non-proliferative Diabetic Retinopathy
por: Cha, Yong Jae, et al.
Publicado: (2007)

Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes
por: Naqvi, S. A. Jaffar, et al.
Publicado: (2016)

Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model
por: Adarkwah, Charles Christian, et al.
Publicado: (2011)

Angiotensin-converting-enzyme inhibitor–induced angioedema
por: Quickfall, Danica, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy
por: Gilbert, Akankwasa, et al.
Publicado: (2018)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with angiotensin-converting enzyme inhibitor therapy
por: Patil, M. R., et al.
Publicado: (2013)

Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine
por: Singh, V. K., et al.
Publicado: (2015)

Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians
por: Park, Ji Young, et al.
Publicado: (2016)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic
por: Cure, Erkan, et al.
Publicado: (2020)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
por: Caballero, Julio
Publicado: (2020)

Structure and Function of Angiotensin Converting Enzyme and Its Inhibitors
por: Zhao, Yulan, et al.
Publicado: (2008)

Discovery and biosynthesis of karnamicins as angiotensin converting enzyme inhibitors
por: Yu, Zhiyin, et al.
Publicado: (2023)

Cost–Utility of Angiotensin-Converting Enzyme Inhibitor-Based Treatment Compared With Thiazide Diuretic-Based Treatment for Hypertension in Elderly Australians Considering Diabetes as Comorbidity
por: Chowdhury, Enayet K., et al.
Publicado: (2015)

Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2009)

Angiotensin-Converting Enzyme Genotype and Peripheral Arterial Disease in Diabetic Patients
por: Tseng, Chin-Hsiao, et al.
Publicado: (2012)

Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2010)

Commentary on “angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic”
por: Ferrario, Carlos M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_grs4qhf9kdcq7rs0i2aqqb05nv